First in Man Evaluation of Single and Multiple Doses of Oral ATX2417
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
First in man evaluation of single and multiple doses of compound ATX2417 in healthy male
volunteers. A double blind placebo controlled parallel group ascending dose design; up to
five dose levels for the single dose and up to two dose levels for the multiple dose (8 days
of dosing). Subjects will be screened to assure normal health prior to inclusion in the trial
and will be monitored for safety (adverse events, vital signs, ECGs, safety labs) and
pharmacokinetic profile. A fasted/fed comparison will also be included in the single
ascending dose part of the trial.